A new study published in the just-published “Oncotarget” peer-reviewed medical journal has concluded that “in the setting of previously treated, advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute for tissue biopsies.
Further refinement in defining the optimal patient population and timing of blood sampling may improve the value of a blood-based test. Read more . . .